3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
17
Thoracic
6
Head & Neck
5
Gastrointestinal
5
Breast
5
Gynecologic
4
Lymphoid
3
Genitourinary
3
CNS
3
Sarcoma
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Endocrine
1
Conditions
Multiple Myeloma
11
Neoplasms, Plasma Cell
5
Waldenstrom Macroglobulinemia
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Lymphoma
3
Sezary Syndrome
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia
2
Intraocular Lymphoma
2
Immunoglobulin Light-chain Amyloidosis
2
Immunoblastic Lymphadenopathy
2
Colonic Neoplasms
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Interventions
fludarabine
3
Cyclophosphamide
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
zimberelimab
1
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
temsirolimus
1
sapanisertib
1
resiquimod
1
relatlimab
1
poly ICLC
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
marizomib
1
larotrectinib
1
ipatasertib
1
interferon-alfa-1b
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
cc-486
1
capivasertib
1
binimetinib
1
adavosertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
Drug Therapy
×
Plasma cell
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled